Sangamo Biosciences reported $-43977000 in Net Income for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Alnylam Pharmaceuticals ALNY:US $ -240.34M 18.12M
Amgen AMGN:US $ 1476M 423M
Avrobio Inc AVRO:US $ -29833000 1.61M
Bayer BAYN:GR € 3291M 2130M
Biocryst Pharmaceuticals BCRX:US $ -74.2M 56.42M
Biogen BIIB:US $ 303.8M 64.4M
Biomarin Pharmaceutical BMRN:US $ 120.8M 178.7M
Gilead Sciences GILD:US $ 19M 363M
GlaxoSmithKline GSK:LN 1802M 1053M
Intercept Pharmaceuticals ICPT:US $ -17.28M 19M
IONIS PHARMACEUT IONS:US $ -65.17M 289.78M
Johnson & Johnson JNJ:US $ 5149M 413M
Karyopharm Therapeutics KPTI:US $ -41399000 80.12M
Merk MRK:US $ 4310M 552M
Novartis NOVN:VX SF 2222M 14086M
Pfizer PFE:US $ 7863M 4470M
Regulus Therapeutics RGLS:US $ -6.72M 0.41M
Sangamo Biosciences SGMO:US $ -43.98M 6.48M
Sarepta Therapeutics SRPT:US $ -105.02M 16.96M
Ultragenyx Pharmaceutical RARE:US $ -152.32M 29.86M
Vertex Pharmaceuticals VRTX:US $ 762.1M 8.01M
Ziopharm Oncology ZIOP:US $ -9.79M 2.01M